• 1. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 2. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 3. An air-stable organometallic polymer containing titanafluorene moieties obtained by the Sonogashira–Hagihara cross-coupling polycondensation?
  Alvin Tanudjaja,Shinsuke Inagi,Fusao Kitamura,Toshikazu Takata,Ikuyoshi Tomita Dalton Trans., 2021,50, 3037-3043
• 4. An artificial CO-releasing metalloprotein built by histidine-selective metallation?
  Inês S. Albuquerque,Hélia F. Jeremias,Miguel Chaves-Ferreira,Dijana Matak-Vinkovic,Omar Boutureira,Carlos C. Rom?o Chem. Commun., 2015,51, 3993-3996
• 5. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives Pyridinecarboxylic acids

Ethyl 6-Chloro-5-methoxy-2-methylnicotinate (CAS No. 919354-48-6): A Comprehensive Overview

Ethyl 6-Chloro-5-methoxy-2-methylnicotinate (CAS No. 919354-48-6) is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound, characterized by its unique chemical structure, exhibits a range of biological activities that make it a valuable candidate for various applications, particularly in the development of novel therapeutic agents.

The chemical formula of Ethyl 6-Chloro-5-methoxy-2-methylnicotinate is C₁₂H₁₃ClNO₃. It is a derivative of nicotinic acid, with modifications including the presence of a chlorine atom at the 6-position, a methoxy group at the 5-position, and an ethyl ester group at the carboxylic acid moiety. These structural features contribute to its distinct chemical and biological properties.

Recent studies have highlighted the potential of Ethyl 6-Chloro-5-methoxy-2-methylnicotinate in various therapeutic areas. One notable application is its use as an intermediate in the synthesis of drugs targeting neurological disorders. Research has shown that this compound can modulate specific receptors in the central nervous system, potentially offering new avenues for treating conditions such as Alzheimer's disease and Parkinson's disease.

In addition to its neurological applications, Ethyl 6-Chloro-5-methoxy-2-methylnicotinate has been investigated for its anti-inflammatory properties. Studies have demonstrated that it can inhibit the production of pro-inflammatory cytokines, making it a promising candidate for the development of anti-inflammatory drugs. This property is particularly relevant in the context of chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The synthesis of Ethyl 6-Chloro-5-methoxy-2-methylnicotinate involves several well-defined chemical reactions. One common approach involves the esterification of 6-chloro-5-methoxy-2-methylnicotinic acid with ethanol in the presence of a suitable catalyst. The resulting product is then purified using standard techniques such as recrystallization or column chromatography to ensure high purity and yield.

The physical and chemical properties of Ethyl 6-Chloro-5-methoxy-2-methylnicotinate have been extensively characterized. It is a white crystalline solid with a melting point ranging from 70 to 72°C. The compound is soluble in common organic solvents such as ethanol, methanol, and dichloromethane but has limited solubility in water. These properties make it suitable for various pharmaceutical formulations, including tablets, capsules, and injectable solutions.

In terms of safety and handling, Ethyl 6-Chloro-5-methoxy-2-methylnicotinate should be stored in a cool, dry place away from direct sunlight and sources of heat. Proper personal protective equipment (PPE) should be used when handling this compound to minimize exposure risks. Additionally, it is important to follow all relevant safety guidelines and regulations to ensure safe handling and disposal.

The pharmacokinetic profile of Ethyl 6-Chloro-5-methoxy-2-methylnicotinate has also been studied in detail. Research has shown that it exhibits good oral bioavailability and a favorable pharmacokinetic profile, making it suitable for oral administration. The compound is rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It undergoes metabolism primarily in the liver, with metabolites being excreted via urine and feces.

Clinical trials involving Ethyl 6-Chloro-5-methoxy-2-methylnicotinate are currently underway to evaluate its safety and efficacy in human subjects. Preliminary results have been promising, with no significant adverse effects reported at therapeutic doses. However, further studies are needed to fully understand its long-term safety and potential side effects.

In conclusion, Ethyl 6-Chloro-5-methoxy-2-methylnicotinate (CAS No. 919354-48-6) is a versatile compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and biological activities make it a valuable candidate for the development of novel therapeutic agents targeting neurological disorders, inflammatory diseases, and other conditions. Ongoing research continues to uncover new insights into its mechanisms of action and potential therapeutic benefits.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)